Trial Profile

Low dose Urokinase therapy in patients with diabetic foot syndrome, critical limb ischemia as well as rest ischemia or missing of option revascularisation in comparison to the standard therapy - randomized, open, controlled phase III study.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Urokinase (Primary)
Indications Diabetic foot ulcer; Embolism and thrombosis; Peripheral ischaemia
Focus Registrational; Therapeutic Use
Acronyms AUGUST-2

07 Apr 2014 Biomarkers information updated
29 Dec 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
13 Jul 2012 New source identified and integrated (ClinicalTrials.gov).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com